Close

Drug Research

FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Hepatitis C is...

Teva’s Dedication and Commitment Recognized by Patients

Fourth annual PatientView survey identifies Teva as a “Corporate Star” in the eyes of patients. Making medicines accessible is key to patient groups. Teva's Dedication and Commitment Recognized by Patients According to 165 patient groups with an interest in neurological conditions,...

AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines at the AstraZeneca MRC UK Centre for Lead Discovery

AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AstraZeneca MRC UK Centre...

AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class ROR? inhibitors to treat auto-immune diseases

AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR?). Inhibitors of this receptor are believed to have potential against a wide range...

AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer

AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a...

Sanofi, Fraunhofer create new natural product center of excellence

French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases. As part of the deal, Sanofi...

Galena Biopharma, Dr. Reddy’s partner for NeuVax in India

Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read